| Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Income (Loss) Per Share |
Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Income (Loss) Per Share
| | |
2026 | | |
2025 | |
| | |
Three Months Ended
March 31, | |
| | |
2026 | | |
2025 | |
| Options to purchase Common Stock | |
| 3,324 | | |
| 3,372 | |
| Warrants to purchase Common Stock | |
| 258,254,405 | | |
| 20,807,539 | |
| Series E-1 Shares | |
| 168,080,419 | | |
| - | |
| Series F-1 Shares | |
| 1,706,493,507 | | |
| - | |
| Series G-1 Shares | |
| 101,343,389 | | |
| - | |
| Purchase rights to purchase Common Stock | |
| 1,505,819,328 | | |
| - | |
| Convertible debt | |
| 3,036,800,486 | | |
| - | |
| Total(1) | |
| 6,776,794,858 | | |
| 20,810,911 | |
| (1) |
The
potentially dilutive securities in the table above include all potentially dilutive securities that are not included in the diluted
net income (loss) per share as per U.S. GAAP, whereas the total Common Stock reserved for future issuance in Note 8
– Convertible and Redeemable Preferred Stock and Stockholders’ Deficit includes the shares that must legally be
reserved based on the applicable instruments’ agreements. |
|
| Schedule of Weighed Average Common Shares Outstanding for Diluted Net Loss Per Share |
The
following table sets forth the computation of net income attributable to common stockholders, weighted average common shares outstanding
for diluted net income per share, and diluted net income per share attributable to common stockholders for the three months ended March
31, 2025 (in thousands, except share and per share amounts).
Schedule of Weighed Average Common Shares Outstanding for Diluted Net Loss Per Share
| | |
Three Months Ended
March 31, 2025 | |
| Numerator: | |
| | |
| Net income attributable to common stockholders | |
$ | 953 | |
| Adjustments: | |
| | |
| Noncash interest expense on convertible debt, net of tax | |
| 577 | |
| Change in fair value of purchase rights | |
| (1,221 | ) |
| Net income attributable to common stockholders | |
$ | 309 | |
| Denominator: | |
| | |
| Weighted average shares used to compute net income attributable to common stockholders, basic | |
| 118,164,046 | |
| Add: | |
| | |
| Pro forma adjustments to reflect assumed conversion of convertible debt | |
| 2,673,516,392 | |
| Pro forma adjustments to reflect assumed exercise of outstanding purchase rights | |
| 1,519,148,899 | |
| Pro forma adjustments to reflect assumed conversion of Series E-1 Shares | |
| 137,712,447 | |
| Pro forma adjustments to reflect assumed conversion of Series F-1 Shares | |
| 1,706,493,507 | |
| Pro forma adjustments | |
| 1,706,493,507 | |
| | |
| | |
| Weighted average shares used to compute net income attributable to common stockholders, diluted | |
| 6,155,035,291 | |
| Net income per share attributable to common stockholders, diluted | |
$ | 0.00 | |
|